Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation

Clara De Simone, Ketty Peris, Gaia Moretta, Giacomo Caldarola, Maria Concetta Fargnoli, Marco Galluzzo, Marina Talamonti, Simone D’Adamio, Sara Tambone, Luca Bianchi

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Objectives: To evaluate efficacy and safety of the anti-IL-17 drug secukinumab in a real-life large cohort of patients with moderate-to-severe plaque psoriasis in Central Italy. Methods: Multicenter, retrospective study with an observation period of up to 52 weeks. Efficacy was assessed by Psoriasis Area and Severity Index (PASI) score; clinical and laboratory examinations were performed at baseline and at weeks 4, 12, 24, 36, and 52. Results: A 90% and a 100% PASI score reduction (PASI90 and PASI100) were reported in 67.5% and 55% of patients at week 12, respectively. A rapid improvement of skin lesions was observed particularly in young patients and in patients naïve to biologics: at week 4, the achievement of PASI90 and PASI100 was higher in younger patients (odds ratio [OR] 0.95, and 0.95; p = 0.003, and 0.005, respectively); PASI90 was achieved by 42.0% of patients naïve to biologics and by 17.0% of patients with prior exposure to biologics (PBT) (OR 0.24; p = 0.001); and PASI100 was reached by 25.5% of naïve patients and 9.8% of PBT (OR 0.28; p = 0.015).The drug was well tolerated. Conclusion: Secukinumab was effective in this real-life analysis, with rapid clinical improvement and long-term maintenance of results.
Original languageEnglish
Pages (from-to)727-735
Number of pages9
JournalExpert Opinion on Biological Therapy
Volume18
DOIs
Publication statusPublished - 2018

Keywords

  • Anti-IL-17
  • Clinical Biochemistry
  • Drug Discovery3003 Pharmaceutical Science
  • PASI100
  • Pharmacology
  • biologic drugs
  • psoriasis
  • real life
  • secukinumab

Fingerprint Dive into the research topics of 'Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation'. Together they form a unique fingerprint.

Cite this